专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08986731B2 Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy 有权
标题翻译：用于光动力学治疗的疏水性光敏剂的聚乙二醇化脂质体制剂
公开(公告)号：US08986731B2
公开(公告)日：2015-03-24
申请号：US11349405
申请日：2006-02-07
申请人： Volker Albrecht , Alfred Fahr , Dietrich Scheglmann , Susanna Gräfe , Wolfgang Neuberger
发明人： Volker Albrecht , Alfred Fahr , Dietrich Scheglmann , Susanna Gräfe , Wolfgang Neuberger
IPC分类号： A61K9/127 , A61K31/407 , A61K31/555 , A61K41/00
CPC分类号： A61K9/1271 , A61K31/407 , A61K31/555 , A61K41/0071
摘要： Pharmaceutical pegylated liposomal formulations for photodynamic therapy are presented. The pegylated liposomal formulation provides therapeutically effective amounts of the photosensitizer for intravenous administration. At least one of the phospholipids in the liposomes has been linked with poly ethylene glycol (PEG) as an integral part of the phospholipids. The formed pegylated liposomes contain the hydrophobic photosensitizer within the lipid bilayer membrane. Pegylation of liposomes carrying the hydrophobic photosensitizer helps to maintain the drug level within the therapeutic window for longer time periods and provides the drug a longer circulating half life in vivo. Further the pegylated formulation of hydrophobic photosensitizers shows improved pharmacokinetics over standard non-liposomal formulations thus enhancing the efficacy of PDT with the pegylated liposomal formulations.
摘要翻译：提出了用于光动力学治疗的药物聚乙二醇化脂质体制剂。聚乙二醇化脂质体制剂提供治疗有效量的用于静脉内施用的光敏剂。脂质体中的至少一种磷脂已经与作为磷脂的组成部分的聚乙二醇（PEG）连接。形成的聚乙二醇化脂质体在脂质双层膜内含有疏水性光敏剂。携带疏水性光敏剂的脂质体的聚乙二醇化有助于在治疗窗口内维持更长时间的药物水平，并使药物在体内延长循环半衰期。此外，疏水性光敏剂的聚乙二醇化制剂显示与标准非脂质体制剂相比改善的药物代谢动力学，从而增强PDT与聚乙二醇化脂质体制剂的功效。

2. 发明授权

US07354599B2 Liposomal formulations of hydrophobic photosensitizer for photodynamic therapy 有权
标题翻译：用于光动力疗法的疏水性光敏剂的脂质体制剂
公开(公告)号：US07354599B2
公开(公告)日：2008-04-08
申请号：US11298729
申请日：2005-12-09
申请人： Volker Albrecht , Alfred Fahr , Dietrich Scheglmann , Susanna Gräfe , Wolfgang Neuberger
发明人： Volker Albrecht , Alfred Fahr , Dietrich Scheglmann , Susanna Gräfe , Wolfgang Neuberger
IPC分类号： A61K9/127
CPC分类号： A61K41/0071 , A61K9/127
摘要： Pharmaceutical liposomal formulations are described for photodynamic therapy comprising a, hydrophobic porphyrin photosensitizer, a monosaccharide and one or more synthetic phospholipids, which are stable in storage especially through freeze-drying process. The liposomal formulations provide therapeutically effective amounts of the photosensitizer for intravenous administration. In particular derivatives of chlorins and bacteriochlorins, such as temoporfin, are, hydrophobic photosensitizers whose efficacy and safety are enhanced by such liposomal formulations. The formulation can be efficiently freeze-dried preserving the size of the liposomal vehicles, and the content of a therapeutically effective amount of the photosensitizer, due to the selection of phospholipids and monosaccharides. The invention also relates to liposome compositions formed upon reconstitution with an aqueous vehicle. The freeze-dried formulation upon reconstitution with a suitable aqueous vehicle forms liposomes that are useful for intravenous administration.
摘要翻译：描述了用于光动力学治疗的药物脂质体制剂，其包括疏水性卟啉光敏剂，单糖和一种或多种合成磷脂，其特别通过冷冻干燥方法在储存中稳定。脂质体制剂提供治疗有效量的用于静脉内给药的光敏剂。特别是二氢卟酚和细菌二氢卟酚的衍生物，如temoporfin，是通过这种脂质体制剂增强其功效和安全性的疏水性光敏剂。由于磷脂和单糖的选择，制剂可以有效地冷冻干燥，保持脂质体载体的大小和治疗有效量的光敏剂的含量。本发明还涉及在用水性载体重建时形成的脂质体组合物。用合适的水性载体重建后的冷冻干燥制剂形成可用于静脉内给药的脂质体。

3. 发明授权

US08815931B2 Oral formulations for tetrapyrrole derivatives 有权
标题翻译：四吡咯衍生物的口服制剂
公开(公告)号：US08815931B2
公开(公告)日：2014-08-26
申请号：US12768244
申请日：2010-04-27
申请人： Susanna Gräfe , Nikolay Nifantiev , Albrecht Volker , Wolfgang Neuberger , Gerhard Wieland , Dietrich Scheglmann , Alfred Fahr , Arno Wiehe
发明人： Susanna Gräfe , Nikolay Nifantiev , Albrecht Volker , Wolfgang Neuberger , Gerhard Wieland , Dietrich Scheglmann , Alfred Fahr , Arno Wiehe
IPC分类号： A61K31/40 , A61K9/127 , A61K31/498 , A61K9/00 , A61K31/409
CPC分类号： A61K31/409 , A61K9/0065 , A61K9/127 , A61K9/1271 , A61K31/498
摘要： Oral formulations and method of formulating photosensitive agents for oral administration during photodynamic therapy (PDT) and Antimicrobial photodynamic therapy (APDT) treatment are presented. The oral formulated photosensitizers show increased solubility and permeability, thus improving the bioavailability of photosensitizers at the treatment site. An orally administered photosensitizer is suitably formulated for mucosal adhesion and absorption via gastrointestinal mucosal membranes. Oral formulation provided herein use lipids and known proteins as carriers for photosensitizers by oral route. Carriers for encapsulating preselected photosensitizers include conventional liposomes, pegylated liposomes, nanoemulsions, nanocrystrals, nanoparticles, fatty emulsions, lipidic formulations, hydrosols, SMEDDS, Alpha-Feto protein (AFP), and Bovine-Serum-Albumin (BSA), fatty emulsions, hot-melt-extrudates and nanoparticles. The oral formulation, in case of a hydrophobic photosensitizer in the present invention, is stabilized using suitable surfactants/solubilizers thus preventing aggregation of the drug in the stomach and until it is absorbed in the duodenum and the small intestine. Oral formulations can be administered in the form of liquid, capsule, tablet, powder, paste or gel. Formulated drugs can be administered orally as one single dose or in multiple doses before administering PDT. In one embodiment Temoporfin (m-THPC) is used as a photosensitizer in the oral formulations. Temoporfin like many hydrophobic photosensitizers are especially suitable to be administered orally because there is no known enzyme system in the mammalian body which can metabolize Temoporfin or similar photosensitizers. Temoporfin can reach the blood system unchanged and fully active after absorption of the formulation in the gastrointestinal tract.
摘要翻译：提出了在光动力治疗（PDT）和抗微生物光动力疗法（APDT）治疗中配制口服光敏剂的口服制剂和方法。口服配制的光敏剂显示增加的溶解度和渗透性，从而提高光敏剂在治疗部位的生物利用度。口服给药的光敏剂适于配制用于通过胃肠粘膜进行粘膜粘附和吸收。本文提供的口服制剂通过口服途径使用脂质和已知蛋白质作为光敏剂的载体。用于封装预选光敏剂的载体包括常规脂质体，聚乙二醇化脂质体，纳米乳剂，纳米胶体，纳米颗粒，脂肪乳剂，脂质制剂，水溶胶，SMEDDS，α-铁蛋白（AFP）和牛血清白蛋白（BSA），脂肪乳剂，热熔融挤出物和纳米颗粒。在本发明的疏水性光敏剂的情况下，使用合适的表面活性剂/增溶剂稳定口服制剂，从而防止药物在胃中的聚集，直到其被吸收到十二指肠和小肠中。口服制剂可以以液体，胶囊，片剂，粉末，糊剂或凝胶的形式施用。配制药物可以在给予PDT之前以一次剂量或多次剂量口服给药。在一个实施方案中，Temoporfin（m-THPC）用作口服制剂中的光敏剂。类似于许多疏水性光敏剂的Temoporfin特别适合于口服给药，因为哺乳动物体内没有已知的可以代谢Temoporfin或类似光敏剂的酶系统。 Temoporfin可以在胃肠道吸收制剂后达到血液系统不变和充分活性。

4. 发明申请

US20100273803A1 Oral Formulations for Tetrapyrrole Derivatives 有权
标题翻译：四吡咯衍生物的口服制剂
公开(公告)号：US20100273803A1
公开(公告)日：2010-10-28
申请号：US12768244
申请日：2010-04-27
申请人： Susanna Gräfe , Nikolay Nifantiev , Albrecht Volker , Wolfgang Neuberger , Gerhard Wieland , Dietrich Scheglmann , Alfred Fahr , Arno Wiehe
发明人： Susanna Gräfe , Nikolay Nifantiev , Albrecht Volker , Wolfgang Neuberger , Gerhard Wieland , Dietrich Scheglmann , Alfred Fahr , Arno Wiehe
IPC分类号： A61K31/498 , C07D241/46 , A61K31/409 , C07D487/22 , A61P35/00 , A61P31/00 , A61K8/49 , A61Q19/00 , A61Q9/00
CPC分类号： A61K31/409 , A61K9/0065 , A61K9/127 , A61K9/1271 , A61K31/498
摘要： Oral formulations and method of formulating photosensitive agents for oral administration during photodynamic therapy (PDT) and Antimicrobial photodynamic therapy (APDT) treatment are presented. The oral formulated photosensitizers show increased solubility and permeability, thus improving the bioavailability of photosensitizers at the treatment site. An orally administered photosensitizer is suitably formulated for mucosal adhesion and absorption via gastrointestinal mucosal membranes. Oral formulation provided herein use lipids and known proteins as carriers for photosensitizers by oral route. Carriers for encapsulating preselected photosensitizers include conventional liposomes, pegylated liposomes, nanoemulsions, nanocrystrals, nanoparticles, fatty emulsions, lipidic formulations, hydrosols, SMEDDS, Alpha-Feto protein (AFP), and Bovine-Serum-Albumin (BSA), fatty emulsions, hot-melt-extrudates and nanoparticles. The oral formulation, in case of a hydrophobic photosensitizer in the present invention, is stabilized using suitable surfactants/solubilizers thus preventing aggregation of the drug in the stomach and until it is absorbed in the duodenum and the small intestine. Oral formulations can be administered in the form of liquid, capsule, tablet, powder, paste or gel. Formulated drugs can be administered orally as one single dose or in multiple doses before administering PDT. In one embodiment Temoporfin (m-THPC) is used as a photosensitizer in the oral formulations. Temoporfin like many hydrophobic photosensitizers are especially suitable to be administered orally because there is no known enzyme system in the mammalian body which can metabolize Temoporfin or similar photosensitizers. Temoporfin can reach the blood system unchanged and fully active after absorption of the formulation in the gastrointestinal tract.
摘要翻译：提出了在光动力治疗（PDT）和抗微生物光动力疗法（APDT）治疗中配制口服光敏剂的口服制剂和方法。口服配制的光敏剂显示增加的溶解度和渗透性，从而提高光敏剂在治疗部位的生物利用度。口服给药的光敏剂适于配制用于通过胃肠粘膜进行粘膜粘附和吸收。本文提供的口服制剂通过口服途径使用脂质和已知蛋白质作为光敏剂的载体。用于封装预选光敏剂的载体包括常规脂质体，聚乙二醇化脂质体，纳米乳剂，纳米胶体，纳米颗粒，脂肪乳剂，脂质制剂，水溶胶，SMEDDS，α-铁蛋白（AFP）和牛血清白蛋白（BSA），脂肪乳剂，热熔融挤出物和纳米颗粒。在本发明的疏水性光敏剂的情况下，使用合适的表面活性剂/增溶剂稳定口服制剂，从而防止药物在胃中的聚集，直到其被吸收到十二指肠和小肠中。口服制剂可以以液体，胶囊，片剂，粉末，糊剂或凝胶的形式施用。配制药物可以在给予PDT之前以一次剂量或多次剂量口服给药。在一个实施方案中，Temoporfin（m-THPC）用作口服制剂中的光敏剂。类似于许多疏水性光敏剂的Temoporfin特别适合于口服给药，因为哺乳动物体内没有已知的可以代谢Temoporfin或类似光敏剂的酶系统。 Temoporfin可以在胃肠道吸收制剂后达到血液系统不变和充分活性。

5. 发明申请

US20120101427A1 NOVEL PHOTOSENSITIZER FORMULATIONS FOR ORAL ADMINISTRATION 审中-公开
标题翻译：用于口腔管理的新型光敏剂配方
公开(公告)号：US20120101427A1
公开(公告)日：2012-04-26
申请号：US13266056
申请日：2009-04-28
申请人： Gerard Farmer , Gerhard Wieland , Dietrich Scheglmann , Arno Wiehe , Susanna Gräfe , Nikolay E. Nufantiev , Volker Albrecht , Wolfgang Neuberger
发明人： Gerard Farmer , Gerhard Wieland , Dietrich Scheglmann , Arno Wiehe , Susanna Gräfe , Nikolay E. Nufantiev , Volker Albrecht , Wolfgang Neuberger
IPC分类号： A61M37/00 , A61K31/498 , C07D487/22 , C07D241/46 , A61K9/127 , A61K38/02 , A61K31/7056 , A61K31/706 , A61K31/79 , A61P35/00 , A61P17/00 , A61P9/00 , A61P19/02 , A61P31/04 , A61P33/02 , A61P31/12 , A61P31/00 , A61K31/409 , B82Y5/00
CPC分类号： A61K31/122 , A61K31/40 , A61K31/498 , A61K41/0071
摘要： The present invention provides novel drug formulations for oral administration for diverse medical applications including anticancer, antimetastatic, antibacterial, antifungal, antiprotozoic, antiviral, antiprionic and PDT treatments for diagnostic and therapeutic purposes. In a preferred embodiment the oral drug formulation comprises a photosensitizer and suitable excipients and may be administered in multiple doses over an extended period of time with exposure to activating radiation occurring generally between individual doses or in a light-independent manner. In another preferred embodiment PDT methods for treating hyperplasia and neoplasia, for localizing hyperplasic and neoplasic tissues and pathogen bacteria by fluorescence, for treating infections caused by pathogen bacteria in complex body fluids and for fat reduction, skin disorders and vascular diseases are provided.
摘要翻译：本发明提供用于口服给药以用于各种医学应用的新型药物制剂，包括用于诊断和治疗目的的抗癌，抗转移，抗细菌，抗真菌，抗原生动脉，抗病毒，抗细胞和PDT治疗。在优选的实施方案中，口服药物制剂包含光敏剂和合适的赋形剂，并且可以在延长的时间段内以多个剂量施用，暴露于通常在单独剂量之间或以轻轻独立的方式发生的活化辐射。在另一个优选实施方案中，提供了用于治疗增生和瘤形成的PDT方法，用于通过荧光定位超基质和新生组织和病原体细菌，用于治疗复杂体液中由病原体引起的感染和用于减脂，皮肤病和血管疾病。

6. 发明申请

US20060088584A1 Liposomal formulations of hydrophobic photosensitizer for photodynamic therapy 有权
标题翻译：用于光动力疗法的疏水性光敏剂的脂质体制剂
公开(公告)号：US20060088584A1
公开(公告)日：2006-04-27
申请号：US11298729
申请日：2005-12-09
申请人： Volker Albrecht , Alfred Fahr , Dietrich Scheglmann , Susanna Grafe , Wolfgang Neuberger
发明人： Volker Albrecht , Alfred Fahr , Dietrich Scheglmann , Susanna Grafe , Wolfgang Neuberger
IPC分类号： A61K9/127 , A61K31/70 , A61K31/409
CPC分类号： A61K41/0071 , A61K9/127
摘要： Pharmaceutical liposomal formulations are described for photodynamic therapy comprising a, hydrophobic porphyrin photosensitizer, a monosaccharide and one or more synthetic phospholipids, which are stable in storage especially through freeze-drying process. The liposomal formulations provide therapeutically effective amounts of the photosensitizer for intravenous administration. In particular derivatives of chlorins and bacteriochlorins, such as temoporfin, are, hydrophobic photosensitizers whose efficacy and safety are enhanced by such liposomal formulations. The formulation can be efficiently freeze-dried preserving the size of the liposomal vehicles, and the content of a therapeutically effective amount of the photosensitizer, due to the selection of phospholipids and monosaccharides. The invention also relates to liposome compositions formed upon reconstitution with an aqueous vehicle. The freeze-dried formulation upon reconstitution with a suitable aqueous vehicle forms liposomes that are useful for intravenous administration.
摘要翻译：描述了用于光动力学治疗的药物脂质体制剂，其包括疏水性卟啉光敏剂，单糖和一种或多种合成磷脂，其特别通过冷冻干燥方法在储存中稳定。脂质体制剂提供治疗有效量的用于静脉内给药的光敏剂。特别是二氢卟酚和细菌二氢卟酚的衍生物，如temoporfin，是通过这种脂质体制剂增强其功效和安全性的疏水性光敏剂。由于磷脂和单糖的选择，制剂可以有效地冷冻干燥，保持脂质体载体的大小和治疗有效量的光敏剂的含量。本发明还涉及在用水性载体重建时形成的脂质体组合物。用合适的水性载体重建后的冷冻干燥制剂形成可用于静脉内给药的脂质体。

7. 发明申请

US20060159740A1 Hydrophobic photosensitizer formulations for photodynamic therapy 审中-公开
标题翻译：用于光动力疗法的疏水性光敏剂配方
公开(公告)号：US20060159740A1
公开(公告)日：2006-07-20
申请号：US11384767
申请日：2006-03-20
申请人： Volker Albrecht , Alfred Fahr , Dietrich Scheglmann , Susanna Grafe , Wolfgang Neuberger
发明人： Volker Albrecht , Alfred Fahr , Dietrich Scheglmann , Susanna Grafe , Wolfgang Neuberger
IPC分类号： A61K31/409 , A61K31/555 , A61K9/127
CPC分类号： A61K41/0071 , A61K9/127
摘要： Pharmaceutical liposomal formulations for photodynamic therapy are presented, which are stable in storage as liquid formulations, comprise a hydrophobic photosensitizer and one or more synthetic phospholipids. The liposomal formulations provide therapeutically effective amounts of the photosensitizer for intravenous administration. The formed liposomes contain the hydrophobic photosensitizer within the lipid bilayer membrane. In the present formulation the size of the liposomal vehicles and their content of a therapeutically effective amount of the photosensitizing agent remain unchanged over storage times of a year or more, thus making the liquid formulations commercially viable. Being stable in the liquid state also makes them easy to store, and easier to use for doctors and patients. They can be prepared in a ‘factory setting’ delivered to practitioners in a liquid state and be available for use in PDT related treatments as called for by the practitioners' patient needs.
摘要翻译：提出了用于光动力学治疗的药物脂质体制剂，其作为液体制剂在储存中稳定，包含疏水性光敏剂和一种或多种合成磷脂。脂质体制剂提供治疗有效量的用于静脉内给药的光敏剂。形成的脂质体在脂质双层膜内含有疏水性光敏剂。在本发明的制剂中，脂质体载体的大小及其治疗有效量的光敏剂的含量在一年以上的保存时间内保持不变，从而使液体制剂在商业上可行。在液体状态下稳定也使得它们易于储存，并且更容易用于医生和患者。他们可以在“工厂设置”下准备就绪，以液体状态送达医生，并可根据医生的病人需要进行PDT相关治疗。

8. 发明申请

US20050048109A1 Non-polar photosensitizer formulations for photodynamic therapy 审中-公开
标题翻译：用于光动力疗法的非极性光敏剂配方
公开(公告)号：US20050048109A1
公开(公告)日：2005-03-03
申请号：US10648168
申请日：2003-08-26
申请人： Volker Albrecht , Alfred Fahr , Dietrich Scheglmann , Susanna Grafe , Wolfgang Neuberger
发明人： Volker Albrecht , Alfred Fahr , Dietrich Scheglmann , Susanna Grafe , Wolfgang Neuberger
IPC分类号： A61K9/127 , A61K41/00
CPC分类号： A61K41/0071 , A61K9/127
摘要： A pharmaceutical liposomal formulation for photodynamic therapy comprising a non-polar porphyrin photosensitizer and one or more phospholipids, which are stable in storage without requiring freeze-drying is described. The liposomal formulation provides therapeutically effective amounts of the photosensitizer for intravenous administration. The phospholipids may be modified by pegylation, i.e. they contain poly ethylene glycol as an integral part of the phospholipids. The formed liposomes contain the non-polar photosensitizer within the membrane and are useful for the combined targeting of a non-polar photosensitizer and a second polar substance. When a formulation includes the presence of monosaccharides or polyalcohols, it can be efficiently freeze-dried preserving the size of the liposomal vehicles and the content of a therapeutically effective amount of the photosensitizing agent. The invention also relates to the liposome composition formed upon reconstitution with an aqueous vehicle. The freeze-dried formulation upon reconstitution with a suitable aqueous vehicle forms liposomes that are also useful for intravenous administration.
摘要翻译：描述了一种用于光动力疗法的药物脂质体制剂，其包含非极性卟啉光敏剂和一种或多种在不需要冷冻干燥的情况下在储存中稳定的磷脂。脂质体制剂提供治疗有效量的用于静脉内施用的光敏剂。可以通过聚乙二醇化来改变磷脂，即它们含有聚乙二醇作为磷脂的组成部分。形成的脂质体在膜内含有非极性光敏剂，并且可用于非极性光敏剂和第二极性物质的组合靶向。当制剂包含单糖或多元醇的存在时，可有效地冷冻干燥保存脂质体载体的大小和治疗有效量的光敏剂的含量。本发明还涉及在与水性载体重建时形成的脂质体组合物。用合适的水性载体重构后的冷冻干燥制剂形成也可用于静脉内施用的脂质体。

9. 发明申请

US20060127471A1 Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy 有权
公开(公告)号：US20060127471A1
公开(公告)日：2006-06-15
申请号：US11349405
申请日：2006-02-07
申请人： Volker Albrecht , Alfred Fahr , Dietrich Schegimann , Susanna Grafe , Wolfgang Neuberger
发明人： Volker Albrecht , Alfred Fahr , Dietrich Schegimann , Susanna Grafe , Wolfgang Neuberger
IPC分类号： A61K31/555 , A61K9/127 , A61K31/407
CPC分类号： A61K9/1271 , A61K31/407 , A61K31/555 , A61K41/0071
摘要： Pharmaceutical pegylated liposomal formulations for photodynamic therapy are presented. The pegylated liposomal formulation provides therapeutically effective amounts of the photosensitizer for intravenous administration. At least one of the phospholipids in the liposomes has been linked with poly ethylene glycol (PEG) as an integral part of the phospholipids. The formed pegylated liposomes contain the hydrophobic photosensitizer within the lipid bilayer membrane. Pegylation of liposomes carrying the hydrophobic photosensitizer helps to maintain the drug level within the therapeutic window for longer time periods and provides the drug a longer circulating half life in vivo. Further the pegylated formulation of hydrophobic photosensitizers shows improved pharmacokinetics over standard non-liposomal formulations thus enhancing the efficacy of PDT with the pegylated liposomal formulations.

10. 发明申请

US20110021973A1 FORMULATIONS FOR COSMETIC AND WOUND CARE TREATMENTS WITH PHOTOSENSITIZERS AS FLUORESCENT MARKERS 审中-公开
标题翻译：使用光敏剂作为荧光标记的化妆和治疗护理品的配方
公开(公告)号：US20110021973A1
公开(公告)日：2011-01-27
申请号：US12896614
申请日：2010-10-01
申请人： Wolfgang Neuberger , Susanna Gräfe , Nikolay E. Nifantiev
发明人： Wolfgang Neuberger , Susanna Gräfe , Nikolay E. Nifantiev
IPC分类号： A61M37/00
CPC分类号： A61L27/50
摘要： Photoactive materials, such as photosensitizers, are used as fluorescent markers for in vivo detection of the distribution of the injected filler material during cosmetic treatments. In one preferred embodiment, liposomal formulated temoporfin is used, as the photoactive component, in very small concentrations along with fillers for cosmetic and wound healing applications. Fillers, which can be used in the invention, include collagen, hyaluronic acids and other synthetic or natural products which are generally used in wound healing, scar reduction and other such medical applications. In a preferred embodiment, the formulated photosensitizer is coupled to the filler so that tracking is possible over longer periods of time A liposomal formulated photosensitizer is injected with the fillers into the treatment area, and is irradiated with laser light shortly after injection. The emitted fluorescence is measured by a special non-invasive device. Thereby it is possible to monitor the injection site and the distribution of the injected solution around the injection site. When irradiated with laser or other light source, the fluorescence of the photosensitizer is detected using a fluorescence detector, which permits tracking the filler at injection site and in the injection volume.
摘要翻译：光敏剂如光敏剂被用作荧光标记物，用于在化妆品处理期间体内检测注入的填充材料的分布。在一个优选的实施方案中，作为光活性成分的脂质体配制的temoporfin以非常小的浓度与用于化妆品和伤口愈合应用的填充剂一起使用。可用于本发明的填充剂包括胶原蛋白，透明质酸和通常用于伤口愈合，瘢痕减少等医学应用中的其它合成或天然产物。在优选的实施方案中，将配制的光敏剂偶联到填料，使得可以在更长时间内进行跟踪。将脂质体配制的光敏剂注射到处理区域中，并在注射后不久用激光照射。发射的荧光通过特殊的非侵入性装置测量。因此，可以监测注射部位和注射部位周围注射溶液的分布情况。当用激光或其他光源照射时，使用荧光检测器检测光敏剂的荧光，其允许在注射部位和注射体积中追踪填料。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式